nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—BRAF—thyroid cancer	0.397	1	CbGaD
Dabrafenib—RAF1—Sorafenib—thyroid cancer	0.175	0.431	CbGbCtD
Dabrafenib—BRAF—Sorafenib—thyroid cancer	0.147	0.361	CbGbCtD
Dabrafenib—ABCG2—Vandetanib—thyroid cancer	0.0276	0.0679	CbGbCtD
Dabrafenib—ABCG2—Sorafenib—thyroid cancer	0.0166	0.0409	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—thyroid cancer	0.0101	0.0248	CbGbCtD
Dabrafenib—CYP2C8—Sorafenib—thyroid cancer	0.00885	0.0218	CbGbCtD
Dabrafenib—ABCB1—Sorafenib—thyroid cancer	0.00599	0.0147	CbGbCtD
Dabrafenib—CYP3A4—Vandetanib—thyroid cancer	0.00595	0.0147	CbGbCtD
Dabrafenib—ABCB1—Doxorubicin—thyroid cancer	0.00363	0.00895	CbGbCtD
Dabrafenib—CYP3A4—Sorafenib—thyroid cancer	0.00359	0.00884	CbGbCtD
Dabrafenib—NEK11—thyroid gland—thyroid cancer	0.00219	0.125	CbGeAlD
Dabrafenib—CYP3A4—Doxorubicin—thyroid cancer	0.00218	0.00536	CbGbCtD
Dabrafenib—LIMK1—thyroid gland—thyroid cancer	0.00157	0.0892	CbGeAlD
Dabrafenib—NEK11—lymph node—thyroid cancer	0.00136	0.0774	CbGeAlD
Dabrafenib—RAF1—neck—thyroid cancer	0.00136	0.0771	CbGeAlD
Dabrafenib—SIK1—saliva-secreting gland—thyroid cancer	0.00133	0.0756	CbGeAlD
Dabrafenib—RAF1—saliva-secreting gland—thyroid cancer	0.00106	0.0602	CbGeAlD
Dabrafenib—LIMK1—lymph node—thyroid cancer	0.000974	0.0554	CbGeAlD
Dabrafenib—BRAF—thyroid gland—thyroid cancer	0.000969	0.0551	CbGeAlD
Dabrafenib—RAF1—trachea—thyroid cancer	0.000816	0.0464	CbGeAlD
Dabrafenib—SIK1—thyroid gland—thyroid cancer	0.000811	0.0461	CbGeAlD
Dabrafenib—SIK1—head—thyroid cancer	0.000719	0.0409	CbGeAlD
Dabrafenib—RAF1—thyroid gland—thyroid cancer	0.000645	0.0367	CbGeAlD
Dabrafenib—BRAF—lymph node—thyroid cancer	0.000602	0.0342	CbGeAlD
Dabrafenib—RAF1—head—thyroid cancer	0.000573	0.0326	CbGeAlD
Dabrafenib—SIK1—lymph node—thyroid cancer	0.000504	0.0287	CbGeAlD
Dabrafenib—ABCG2—saliva-secreting gland—thyroid cancer	0.000438	0.0249	CbGeAlD
Dabrafenib—RAF1—lymph node—thyroid cancer	0.000401	0.0228	CbGeAlD
Dabrafenib—SLC22A8—head—thyroid cancer	0.000333	0.0189	CbGeAlD
Dabrafenib—ABCG2—thyroid gland—thyroid cancer	0.000267	0.0152	CbGeAlD
Dabrafenib—Thrombocytopenia—Vandetanib—thyroid cancer	0.000238	0.00223	CcSEcCtD
Dabrafenib—Skin disorder—Vandetanib—thyroid cancer	0.000236	0.00221	CcSEcCtD
Dabrafenib—Cyst—Doxorubicin—thyroid cancer	0.000235	0.0022	CcSEcCtD
Dabrafenib—Haemoglobin—Sorafenib—thyroid cancer	0.000232	0.00217	CcSEcCtD
Dabrafenib—Haemorrhage—Sorafenib—thyroid cancer	0.00023	0.00216	CcSEcCtD
Dabrafenib—Vaginal haemorrhage—Epirubicin—thyroid cancer	0.000229	0.00215	CcSEcCtD
Dabrafenib—Urinary tract disorder—Sorafenib—thyroid cancer	0.000227	0.00213	CcSEcCtD
Dabrafenib—Connective tissue disorder—Sorafenib—thyroid cancer	0.000226	0.00212	CcSEcCtD
Dabrafenib—Urethral disorder—Sorafenib—thyroid cancer	0.000226	0.00212	CcSEcCtD
Dabrafenib—Hypercalcaemia—Doxorubicin—thyroid cancer	0.000226	0.00212	CcSEcCtD
Dabrafenib—Rash erythematous—Epirubicin—thyroid cancer	0.000221	0.00208	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000221	0.00207	CcSEcCtD
Dabrafenib—Insomnia—Vandetanib—thyroid cancer	0.000219	0.00206	CcSEcCtD
Dabrafenib—Rash pustular—Epirubicin—thyroid cancer	0.000213	0.00199	CcSEcCtD
Dabrafenib—Vaginal haemorrhage—Doxorubicin—thyroid cancer	0.000212	0.00199	CcSEcCtD
Dabrafenib—Decreased appetite—Vandetanib—thyroid cancer	0.000211	0.00198	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000209	0.00197	CcSEcCtD
Dabrafenib—Fatigue—Vandetanib—thyroid cancer	0.000209	0.00196	CcSEcCtD
Dabrafenib—Angiopathy—Sorafenib—thyroid cancer	0.000209	0.00196	CcSEcCtD
Dabrafenib—Immune system disorder—Sorafenib—thyroid cancer	0.000208	0.00195	CcSEcCtD
Dabrafenib—Rigors—Epirubicin—thyroid cancer	0.000208	0.00195	CcSEcCtD
Dabrafenib—Mediastinal disorder—Sorafenib—thyroid cancer	0.000208	0.00195	CcSEcCtD
Dabrafenib—Constipation—Vandetanib—thyroid cancer	0.000207	0.00195	CcSEcCtD
Dabrafenib—Arrhythmia—Sorafenib—thyroid cancer	0.000206	0.00193	CcSEcCtD
Dabrafenib—Rash erythematous—Doxorubicin—thyroid cancer	0.000205	0.00192	CcSEcCtD
Dabrafenib—Alopecia—Sorafenib—thyroid cancer	0.000204	0.00191	CcSEcCtD
Dabrafenib—Mental disorder—Sorafenib—thyroid cancer	0.000202	0.00189	CcSEcCtD
Dabrafenib—Malnutrition—Sorafenib—thyroid cancer	0.000201	0.00188	CcSEcCtD
Dabrafenib—Erythema—Sorafenib—thyroid cancer	0.000201	0.00188	CcSEcCtD
Dabrafenib—Neoplasm malignant—Epirubicin—thyroid cancer	0.000199	0.00186	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000198	0.00186	CcSEcCtD
Dabrafenib—Rash pustular—Doxorubicin—thyroid cancer	0.000197	0.00185	CcSEcCtD
Dabrafenib—Muscle spasms—Sorafenib—thyroid cancer	0.000193	0.00181	CcSEcCtD
Dabrafenib—Rigors—Doxorubicin—thyroid cancer	0.000192	0.0018	CcSEcCtD
Dabrafenib—Abdominal pain—Vandetanib—thyroid cancer	0.000192	0.0018	CcSEcCtD
Dabrafenib—Body temperature increased—Vandetanib—thyroid cancer	0.000192	0.0018	CcSEcCtD
Dabrafenib—Bone disorder—Epirubicin—thyroid cancer	0.000188	0.00176	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Epirubicin—thyroid cancer	0.000186	0.00175	CcSEcCtD
Dabrafenib—Cellulitis—Epirubicin—thyroid cancer	0.000186	0.00175	CcSEcCtD
Dabrafenib—Anaemia—Sorafenib—thyroid cancer	0.000185	0.00174	CcSEcCtD
Dabrafenib—Hypocalcaemia—Epirubicin—thyroid cancer	0.000185	0.00174	CcSEcCtD
Dabrafenib—Neoplasm malignant—Doxorubicin—thyroid cancer	0.000184	0.00172	CcSEcCtD
Dabrafenib—Leukopenia—Sorafenib—thyroid cancer	0.000179	0.00168	CcSEcCtD
Dabrafenib—Creatinine increased—Epirubicin—thyroid cancer	0.000178	0.00167	CcSEcCtD
Dabrafenib—Cough—Sorafenib—thyroid cancer	0.000175	0.00164	CcSEcCtD
Dabrafenib—Asthenia—Vandetanib—thyroid cancer	0.000174	0.00163	CcSEcCtD
Dabrafenib—Bone disorder—Doxorubicin—thyroid cancer	0.000174	0.00163	CcSEcCtD
Dabrafenib—Hypertension—Sorafenib—thyroid cancer	0.000173	0.00162	CcSEcCtD
Dabrafenib—Cellulitis—Doxorubicin—thyroid cancer	0.000172	0.00162	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	0.000172	0.00162	CcSEcCtD
Dabrafenib—Pruritus—Vandetanib—thyroid cancer	0.000172	0.00161	CcSEcCtD
Dabrafenib—Hypocalcaemia—Doxorubicin—thyroid cancer	0.000171	0.00161	CcSEcCtD
Dabrafenib—Arthralgia—Sorafenib—thyroid cancer	0.000171	0.0016	CcSEcCtD
Dabrafenib—Myalgia—Sorafenib—thyroid cancer	0.000171	0.0016	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00017	0.00159	CcSEcCtD
Dabrafenib—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.00017	0.00159	CcSEcCtD
Dabrafenib—Dry mouth—Sorafenib—thyroid cancer	0.000167	0.00157	CcSEcCtD
Dabrafenib—Hyperkalaemia—Epirubicin—thyroid cancer	0.000167	0.00156	CcSEcCtD
Dabrafenib—ABCB1—trachea—thyroid cancer	0.000166	0.00947	CbGeAlD
Dabrafenib—Diarrhoea—Vandetanib—thyroid cancer	0.000166	0.00156	CcSEcCtD
Dabrafenib—ABCG2—lymph node—thyroid cancer	0.000166	0.00944	CbGeAlD
Dabrafenib—Creatinine increased—Doxorubicin—thyroid cancer	0.000165	0.00155	CcSEcCtD
Dabrafenib—Influenza like illness—Epirubicin—thyroid cancer	0.000165	0.00154	CcSEcCtD
Dabrafenib—Infection—Sorafenib—thyroid cancer	0.000163	0.00153	CcSEcCtD
Dabrafenib—Nervous system disorder—Sorafenib—thyroid cancer	0.00016	0.00151	CcSEcCtD
Dabrafenib—Dizziness—Vandetanib—thyroid cancer	0.00016	0.00151	CcSEcCtD
Dabrafenib—Thrombocytopenia—Sorafenib—thyroid cancer	0.00016	0.0015	CcSEcCtD
Dabrafenib—Skin disorder—Sorafenib—thyroid cancer	0.000159	0.00149	CcSEcCtD
Dabrafenib—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.000157	0.00147	CcSEcCtD
Dabrafenib—Vomiting—Vandetanib—thyroid cancer	0.000154	0.00145	CcSEcCtD
Dabrafenib—Hyperkalaemia—Doxorubicin—thyroid cancer	0.000154	0.00145	CcSEcCtD
Dabrafenib—Rash maculo-papular—Epirubicin—thyroid cancer	0.000154	0.00145	CcSEcCtD
Dabrafenib—Neoplasm—Epirubicin—thyroid cancer	0.000153	0.00144	CcSEcCtD
Dabrafenib—Rash—Vandetanib—thyroid cancer	0.000153	0.00144	CcSEcCtD
Dabrafenib—Dermatitis—Vandetanib—thyroid cancer	0.000153	0.00143	CcSEcCtD
Dabrafenib—Influenza like illness—Doxorubicin—thyroid cancer	0.000152	0.00143	CcSEcCtD
Dabrafenib—Headache—Vandetanib—thyroid cancer	0.000152	0.00143	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000149	0.0014	CcSEcCtD
Dabrafenib—Nausea—Vandetanib—thyroid cancer	0.000144	0.00135	CcSEcCtD
Dabrafenib—Rash maculo-papular—Doxorubicin—thyroid cancer	0.000143	0.00134	CcSEcCtD
Dabrafenib—Decreased appetite—Sorafenib—thyroid cancer	0.000142	0.00134	CcSEcCtD
Dabrafenib—Neoplasm—Doxorubicin—thyroid cancer	0.000142	0.00133	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.000141	0.00133	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000141	0.00133	CcSEcCtD
Dabrafenib—Fatigue—Sorafenib—thyroid cancer	0.000141	0.00132	CcSEcCtD
Dabrafenib—Constipation—Sorafenib—thyroid cancer	0.00014	0.00131	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000136	0.00127	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000134	0.00126	CcSEcCtD
Dabrafenib—Renal failure acute—Epirubicin—thyroid cancer	0.000133	0.00125	CcSEcCtD
Dabrafenib—ABCB1—thyroid gland—thyroid cancer	0.000132	0.00749	CbGeAlD
Dabrafenib—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000131	0.00123	CcSEcCtD
Dabrafenib—Abdominal pain—Sorafenib—thyroid cancer	0.000129	0.00121	CcSEcCtD
Dabrafenib—Body temperature increased—Sorafenib—thyroid cancer	0.000129	0.00121	CcSEcCtD
Dabrafenib—Dermatitis bullous—Epirubicin—thyroid cancer	0.000129	0.00121	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000126	0.00118	CcSEcCtD
Dabrafenib—Hyponatraemia—Epirubicin—thyroid cancer	0.000124	0.00116	CcSEcCtD
Dabrafenib—Renal failure acute—Doxorubicin—thyroid cancer	0.000123	0.00116	CcSEcCtD
Dabrafenib—Pain in extremity—Epirubicin—thyroid cancer	0.000123	0.00115	CcSEcCtD
Dabrafenib—Hypersensitivity—Sorafenib—thyroid cancer	0.000121	0.00113	CcSEcCtD
Dabrafenib—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000119	0.00112	CcSEcCtD
Dabrafenib—Asthenia—Sorafenib—thyroid cancer	0.000117	0.0011	CcSEcCtD
Dabrafenib—ABCB1—head—thyroid cancer	0.000117	0.00664	CbGeAlD
Dabrafenib—Pruritus—Sorafenib—thyroid cancer	0.000116	0.00109	CcSEcCtD
Dabrafenib—Blood creatinine increased—Epirubicin—thyroid cancer	0.000115	0.00108	CcSEcCtD
Dabrafenib—Dehydration—Epirubicin—thyroid cancer	0.000114	0.00107	CcSEcCtD
Dabrafenib—Hyponatraemia—Doxorubicin—thyroid cancer	0.000114	0.00107	CcSEcCtD
Dabrafenib—Pain in extremity—Doxorubicin—thyroid cancer	0.000114	0.00107	CcSEcCtD
Dabrafenib—Dry skin—Epirubicin—thyroid cancer	0.000113	0.00106	CcSEcCtD
Dabrafenib—Abdominal pain upper—Epirubicin—thyroid cancer	0.000112	0.00105	CcSEcCtD
Dabrafenib—Hypokalaemia—Epirubicin—thyroid cancer	0.000112	0.00105	CcSEcCtD
Dabrafenib—Diarrhoea—Sorafenib—thyroid cancer	0.000112	0.00105	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000111	0.00104	CcSEcCtD
Dabrafenib—Nasopharyngitis—Epirubicin—thyroid cancer	0.00011	0.00103	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000109	0.00102	CcSEcCtD
Dabrafenib—Dizziness—Sorafenib—thyroid cancer	0.000108	0.00102	CcSEcCtD
Dabrafenib—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000107	0.001	CcSEcCtD
Dabrafenib—Dehydration—Doxorubicin—thyroid cancer	0.000106	0.000994	CcSEcCtD
Dabrafenib—Dry skin—Doxorubicin—thyroid cancer	0.000104	0.000979	CcSEcCtD
Dabrafenib—Pancreatitis—Epirubicin—thyroid cancer	0.000104	0.000979	CcSEcCtD
Dabrafenib—Vomiting—Sorafenib—thyroid cancer	0.000104	0.000976	CcSEcCtD
Dabrafenib—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000104	0.000976	CcSEcCtD
Dabrafenib—Hypokalaemia—Doxorubicin—thyroid cancer	0.000104	0.000972	CcSEcCtD
Dabrafenib—Rash—Sorafenib—thyroid cancer	0.000103	0.000968	CcSEcCtD
Dabrafenib—Dermatitis—Sorafenib—thyroid cancer	0.000103	0.000967	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000103	0.000962	CcSEcCtD
Dabrafenib—Headache—Sorafenib—thyroid cancer	0.000103	0.000962	CcSEcCtD
Dabrafenib—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000102	0.000955	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.0001	0.000942	CcSEcCtD
Dabrafenib—Neutropenia—Epirubicin—thyroid cancer	9.95e-05	0.000933	CcSEcCtD
Dabrafenib—Nausea—Sorafenib—thyroid cancer	9.72e-05	0.000912	CcSEcCtD
Dabrafenib—Pancreatitis—Doxorubicin—thyroid cancer	9.65e-05	0.000905	CcSEcCtD
Dabrafenib—Hyperglycaemia—Epirubicin—thyroid cancer	9.59e-05	0.0009	CcSEcCtD
Dabrafenib—Infestation NOS—Epirubicin—thyroid cancer	9.48e-05	0.00089	CcSEcCtD
Dabrafenib—Infestation—Epirubicin—thyroid cancer	9.48e-05	0.00089	CcSEcCtD
Dabrafenib—Renal failure—Epirubicin—thyroid cancer	9.32e-05	0.000875	CcSEcCtD
Dabrafenib—Stomatitis—Epirubicin—thyroid cancer	9.24e-05	0.000867	CcSEcCtD
Dabrafenib—Urinary tract infection—Epirubicin—thyroid cancer	9.22e-05	0.000865	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—thyroid cancer	9.2e-05	0.000864	CcSEcCtD
Dabrafenib—Haematuria—Epirubicin—thyroid cancer	9.04e-05	0.000849	CcSEcCtD
Dabrafenib—Epistaxis—Epirubicin—thyroid cancer	8.94e-05	0.000839	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—thyroid cancer	8.88e-05	0.000833	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—thyroid cancer	8.77e-05	0.000823	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—thyroid cancer	8.77e-05	0.000823	CcSEcCtD
Dabrafenib—Renal failure—Doxorubicin—thyroid cancer	8.63e-05	0.000809	CcSEcCtD
Dabrafenib—Haemoglobin—Epirubicin—thyroid cancer	8.56e-05	0.000803	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—thyroid cancer	8.55e-05	0.000803	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—thyroid cancer	8.53e-05	0.0008	CcSEcCtD
Dabrafenib—Haemorrhage—Epirubicin—thyroid cancer	8.51e-05	0.000799	CcSEcCtD
Dabrafenib—Urinary tract disorder—Epirubicin—thyroid cancer	8.41e-05	0.000789	CcSEcCtD
Dabrafenib—Oedema peripheral—Epirubicin—thyroid cancer	8.39e-05	0.000787	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—thyroid cancer	8.37e-05	0.000785	CcSEcCtD
Dabrafenib—Connective tissue disorder—Epirubicin—thyroid cancer	8.37e-05	0.000785	CcSEcCtD
Dabrafenib—Urethral disorder—Epirubicin—thyroid cancer	8.34e-05	0.000783	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—thyroid cancer	8.28e-05	0.000777	CcSEcCtD
Dabrafenib—ABCB1—lymph node—thyroid cancer	8.18e-05	0.00465	CbGeAlD
Dabrafenib—Eye disorder—Epirubicin—thyroid cancer	7.96e-05	0.000747	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—thyroid cancer	7.92e-05	0.000743	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—thyroid cancer	7.88e-05	0.000739	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—thyroid cancer	7.78e-05	0.00073	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—thyroid cancer	7.76e-05	0.000728	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—thyroid cancer	7.74e-05	0.000726	CcSEcCtD
Dabrafenib—Angiopathy—Epirubicin—thyroid cancer	7.72e-05	0.000725	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—thyroid cancer	7.72e-05	0.000725	CcSEcCtD
Dabrafenib—Immune system disorder—Epirubicin—thyroid cancer	7.69e-05	0.000722	CcSEcCtD
Dabrafenib—Mediastinal disorder—Epirubicin—thyroid cancer	7.67e-05	0.00072	CcSEcCtD
Dabrafenib—Chills—Epirubicin—thyroid cancer	7.64e-05	0.000717	CcSEcCtD
Dabrafenib—Arrhythmia—Epirubicin—thyroid cancer	7.6e-05	0.000714	CcSEcCtD
Dabrafenib—Alopecia—Epirubicin—thyroid cancer	7.52e-05	0.000706	CcSEcCtD
Dabrafenib—Mental disorder—Epirubicin—thyroid cancer	7.46e-05	0.0007	CcSEcCtD
Dabrafenib—Erythema—Epirubicin—thyroid cancer	7.41e-05	0.000695	CcSEcCtD
Dabrafenib—Malnutrition—Epirubicin—thyroid cancer	7.41e-05	0.000695	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—thyroid cancer	7.36e-05	0.000691	CcSEcCtD
Dabrafenib—Back pain—Epirubicin—thyroid cancer	7.17e-05	0.000673	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—thyroid cancer	7.15e-05	0.000671	CcSEcCtD
Dabrafenib—Muscle spasms—Epirubicin—thyroid cancer	7.12e-05	0.000669	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—thyroid cancer	7.11e-05	0.000668	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—thyroid cancer	7.1e-05	0.000666	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—thyroid cancer	7.07e-05	0.000663	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—thyroid cancer	7.04e-05	0.00066	CcSEcCtD
Dabrafenib—Vision blurred—Epirubicin—thyroid cancer	6.98e-05	0.000655	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—thyroid cancer	6.96e-05	0.000653	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—thyroid cancer	6.9e-05	0.000648	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—thyroid cancer	6.86e-05	0.000643	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—thyroid cancer	6.86e-05	0.000643	CcSEcCtD
Dabrafenib—Anaemia—Epirubicin—thyroid cancer	6.85e-05	0.000643	CcSEcCtD
Dabrafenib—Leukopenia—Epirubicin—thyroid cancer	6.63e-05	0.000623	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—thyroid cancer	6.63e-05	0.000622	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—thyroid cancer	6.59e-05	0.000619	CcSEcCtD
Dabrafenib—Cough—Epirubicin—thyroid cancer	6.47e-05	0.000607	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—thyroid cancer	6.46e-05	0.000606	CcSEcCtD
Dabrafenib—Hypertension—Epirubicin—thyroid cancer	6.4e-05	0.0006	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—thyroid cancer	6.34e-05	0.000595	CcSEcCtD
Dabrafenib—Myalgia—Epirubicin—thyroid cancer	6.31e-05	0.000592	CcSEcCtD
Dabrafenib—Arthralgia—Epirubicin—thyroid cancer	6.31e-05	0.000592	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	6.27e-05	0.000588	CcSEcCtD
Dabrafenib—Dry mouth—Epirubicin—thyroid cancer	6.17e-05	0.000579	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—thyroid cancer	6.14e-05	0.000576	CcSEcCtD
Dabrafenib—Oedema—Epirubicin—thyroid cancer	6.05e-05	0.000568	CcSEcCtD
Dabrafenib—Infection—Epirubicin—thyroid cancer	6.01e-05	0.000564	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—thyroid cancer	5.98e-05	0.000562	CcSEcCtD
Dabrafenib—Nervous system disorder—Epirubicin—thyroid cancer	5.93e-05	0.000557	CcSEcCtD
Dabrafenib—Thrombocytopenia—Epirubicin—thyroid cancer	5.92e-05	0.000556	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—thyroid cancer	5.92e-05	0.000556	CcSEcCtD
Dabrafenib—Skin disorder—Epirubicin—thyroid cancer	5.87e-05	0.000551	CcSEcCtD
Dabrafenib—Hyperhidrosis—Epirubicin—thyroid cancer	5.85e-05	0.000549	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—thyroid cancer	5.84e-05	0.000548	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—thyroid cancer	5.84e-05	0.000548	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	5.8e-05	0.000544	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—thyroid cancer	5.71e-05	0.000536	CcSEcCtD
Dabrafenib—Hypotension—Epirubicin—thyroid cancer	5.65e-05	0.00053	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—thyroid cancer	5.6e-05	0.000525	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—thyroid cancer	5.56e-05	0.000522	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	5.51e-05	0.000517	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—thyroid cancer	5.49e-05	0.000515	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—thyroid cancer	5.48e-05	0.000514	CcSEcCtD
Dabrafenib—Insomnia—Epirubicin—thyroid cancer	5.47e-05	0.000513	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—thyroid cancer	5.44e-05	0.00051	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—thyroid cancer	5.41e-05	0.000508	CcSEcCtD
Dabrafenib—Decreased appetite—Epirubicin—thyroid cancer	5.26e-05	0.000493	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—thyroid cancer	5.23e-05	0.000491	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Epirubicin—thyroid cancer	5.22e-05	0.00049	CcSEcCtD
Dabrafenib—Fatigue—Epirubicin—thyroid cancer	5.21e-05	0.000489	CcSEcCtD
Dabrafenib—Constipation—Epirubicin—thyroid cancer	5.17e-05	0.000485	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	5.1e-05	0.000478	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—thyroid cancer	5.06e-05	0.000475	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Epirubicin—thyroid cancer	4.95e-05	0.000464	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—thyroid cancer	4.86e-05	0.000457	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	4.83e-05	0.000453	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—thyroid cancer	4.82e-05	0.000453	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—thyroid cancer	4.79e-05	0.000449	CcSEcCtD
Dabrafenib—Body temperature increased—Epirubicin—thyroid cancer	4.78e-05	0.000449	CcSEcCtD
Dabrafenib—Abdominal pain—Epirubicin—thyroid cancer	4.78e-05	0.000449	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—thyroid cancer	4.58e-05	0.000429	CcSEcCtD
Dabrafenib—Hypersensitivity—Epirubicin—thyroid cancer	4.46e-05	0.000418	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—thyroid cancer	4.42e-05	0.000415	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—thyroid cancer	4.42e-05	0.000415	CcSEcCtD
Dabrafenib—Asthenia—Epirubicin—thyroid cancer	4.34e-05	0.000407	CcSEcCtD
Dabrafenib—Pruritus—Epirubicin—thyroid cancer	4.28e-05	0.000402	CcSEcCtD
Dabrafenib—Diarrhoea—Epirubicin—thyroid cancer	4.14e-05	0.000388	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—thyroid cancer	4.12e-05	0.000387	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—thyroid cancer	4.02e-05	0.000377	CcSEcCtD
Dabrafenib—Dizziness—Epirubicin—thyroid cancer	4e-05	0.000375	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—thyroid cancer	3.96e-05	0.000372	CcSEcCtD
Dabrafenib—Vomiting—Epirubicin—thyroid cancer	3.85e-05	0.000361	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—thyroid cancer	3.83e-05	0.000359	CcSEcCtD
Dabrafenib—Rash—Epirubicin—thyroid cancer	3.81e-05	0.000358	CcSEcCtD
Dabrafenib—Dermatitis—Epirubicin—thyroid cancer	3.81e-05	0.000358	CcSEcCtD
Dabrafenib—Headache—Epirubicin—thyroid cancer	3.79e-05	0.000356	CcSEcCtD
Dabrafenib—Dizziness—Doxorubicin—thyroid cancer	3.7e-05	0.000347	CcSEcCtD
Dabrafenib—Nausea—Epirubicin—thyroid cancer	3.59e-05	0.000337	CcSEcCtD
Dabrafenib—Vomiting—Doxorubicin—thyroid cancer	3.56e-05	0.000334	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—thyroid cancer	3.53e-05	0.000331	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—thyroid cancer	3.53e-05	0.000331	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—thyroid cancer	3.51e-05	0.000329	CcSEcCtD
Dabrafenib—Nausea—Doxorubicin—thyroid cancer	3.32e-05	0.000312	CcSEcCtD
Dabrafenib—RAF1—Signaling by FGFR in disease—KRAS—thyroid cancer	2.05e-05	0.000282	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KRAS—thyroid cancer	2.05e-05	0.000282	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TPR—thyroid cancer	2.05e-05	0.000281	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PRKAR1A—thyroid cancer	2.04e-05	0.00028	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	2.04e-05	0.00028	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—KRAS—thyroid cancer	2.03e-05	0.000279	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—KRAS—thyroid cancer	2.02e-05	0.000277	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PRKAR1A—thyroid cancer	2.01e-05	0.000277	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—KRAS—thyroid cancer	2.01e-05	0.000277	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.01e-05	0.000276	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDK1—thyroid cancer	2e-05	0.000276	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CHST14—thyroid cancer	2e-05	0.000276	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—KRAS—thyroid cancer	2e-05	0.000276	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—HRAS—thyroid cancer	2e-05	0.000275	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NRG1—thyroid cancer	1.99e-05	0.000273	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	1.97e-05	0.000271	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—HRAS—thyroid cancer	1.97e-05	0.000271	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TCF7L1—thyroid cancer	1.96e-05	0.000269	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—HRAS—thyroid cancer	1.96e-05	0.000269	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—AKT1—thyroid cancer	1.95e-05	0.000269	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MEN1—thyroid cancer	1.95e-05	0.000268	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—AKT1—thyroid cancer	1.94e-05	0.000267	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	1.93e-05	0.000265	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MEN1—thyroid cancer	1.92e-05	0.000265	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—thyroid cancer	1.9e-05	0.000261	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—HRAS—thyroid cancer	1.89e-05	0.00026	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—SST—thyroid cancer	1.89e-05	0.000259	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—HRAS—thyroid cancer	1.88e-05	0.000258	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—HRAS—thyroid cancer	1.87e-05	0.000257	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—HRAS—thyroid cancer	1.87e-05	0.000257	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—HRAS—thyroid cancer	1.86e-05	0.000256	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NDUFA13—thyroid cancer	1.86e-05	0.000255	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—HRAS—thyroid cancer	1.85e-05	0.000255	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—AKT1—thyroid cancer	1.84e-05	0.000254	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—RXRA—thyroid cancer	1.83e-05	0.000252	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—PTEN—thyroid cancer	1.82e-05	0.00025	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CALCA—thyroid cancer	1.82e-05	0.00025	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	1.81e-05	0.00025	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—AKT1—thyroid cancer	1.81e-05	0.000249	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—SLC5A5—thyroid cancer	1.8e-05	0.000247	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—AKT1—thyroid cancer	1.76e-05	0.000243	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTCH1—thyroid cancer	1.76e-05	0.000242	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	1.75e-05	0.000241	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—HRAS—thyroid cancer	1.75e-05	0.000241	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—PTEN—thyroid cancer	1.74e-05	0.00024	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CHST14—thyroid cancer	1.74e-05	0.00024	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—HRAS—thyroid cancer	1.74e-05	0.00024	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	1.74e-05	0.00024	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—HRAS—thyroid cancer	1.74e-05	0.00024	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—AKT1—thyroid cancer	1.74e-05	0.000239	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—AKT1—thyroid cancer	1.73e-05	0.000238	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—HRAS—thyroid cancer	1.73e-05	0.000237	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	1.72e-05	0.000237	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	1.72e-05	0.000237	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—HRAS—thyroid cancer	1.71e-05	0.000236	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	1.71e-05	0.000236	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—PPARG—thyroid cancer	1.71e-05	0.000235	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—HRAS—thyroid cancer	1.71e-05	0.000235	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—HRAS—thyroid cancer	1.7e-05	0.000234	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	1.7e-05	0.000233	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.68e-05	0.000232	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—AKT1—thyroid cancer	1.67e-05	0.000229	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—AKT1—thyroid cancer	1.66e-05	0.000228	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—AKT1—thyroid cancer	1.65e-05	0.000227	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—AKT1—thyroid cancer	1.65e-05	0.000227	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—NRAS—thyroid cancer	1.65e-05	0.000227	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—HRAS—thyroid cancer	1.64e-05	0.000226	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CDK1—thyroid cancer	1.64e-05	0.000226	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—AKT1—thyroid cancer	1.64e-05	0.000226	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—AKT1—thyroid cancer	1.63e-05	0.000225	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—NRAS—thyroid cancer	1.62e-05	0.000223	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HPGD—thyroid cancer	1.61e-05	0.000222	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TPR—thyroid cancer	1.61e-05	0.000222	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SST—thyroid cancer	1.61e-05	0.000222	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NRG1—thyroid cancer	1.61e-05	0.000221	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—AKT1—thyroid cancer	1.6e-05	0.00022	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	1.6e-05	0.00022	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PRKAR1A—thyroid cancer	1.59e-05	0.000218	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—HRAS—thyroid cancer	1.58e-05	0.000217	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—NRAS—thyroid cancer	1.56e-05	0.000214	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CALCA—thyroid cancer	1.55e-05	0.000213	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	1.54e-05	0.000212	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	1.54e-05	0.000211	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—AKT1—thyroid cancer	1.54e-05	0.000211	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—AKT1—thyroid cancer	1.54e-05	0.000211	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CALCA—thyroid cancer	1.53e-05	0.000211	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—AKT1—thyroid cancer	1.52e-05	0.00021	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—AKT1—thyroid cancer	1.51e-05	0.000208	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—RXRA—thyroid cancer	1.51e-05	0.000208	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—AKT1—thyroid cancer	1.51e-05	0.000208	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—AKT1—thyroid cancer	1.5e-05	0.000207	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDK1—thyroid cancer	1.5e-05	0.000207	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TPR—thyroid cancer	1.49e-05	0.000206	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	1.49e-05	0.000205	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PRKAR1A—thyroid cancer	1.47e-05	0.000202	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.47e-05	0.000202	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—NRAS—thyroid cancer	1.47e-05	0.000202	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—AKT1—thyroid cancer	1.45e-05	0.0002	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.45e-05	0.000199	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TERT—thyroid cancer	1.44e-05	0.000199	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNA2—thyroid cancer	1.44e-05	0.000199	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.44e-05	0.000198	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TSHR—thyroid cancer	1.43e-05	0.000197	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—KRAS—thyroid cancer	1.42e-05	0.000195	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PRKAR1A—thyroid cancer	1.41e-05	0.000194	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HPGD—thyroid cancer	1.41e-05	0.000194	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDK1—thyroid cancer	1.4e-05	0.000193	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—KRAS—thyroid cancer	1.4e-05	0.000192	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDK1—thyroid cancer	1.39e-05	0.000191	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HIF1A—thyroid cancer	1.38e-05	0.00019	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	1.36e-05	0.000187	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	1.36e-05	0.000187	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MEN1—thyroid cancer	1.35e-05	0.000185	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MINPP1—thyroid cancer	1.34e-05	0.000185	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—KRAS—thyroid cancer	1.34e-05	0.000184	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.31e-05	0.00018	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	1.29e-05	0.000178	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	1.29e-05	0.000177	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—KRAS—thyroid cancer	1.26e-05	0.000174	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	1.23e-05	0.000169	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTCH1—thyroid cancer	1.22e-05	0.000168	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—HRAS—thyroid cancer	1.21e-05	0.000166	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—SLC5A5—thyroid cancer	1.21e-05	0.000166	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HRAS—thyroid cancer	1.21e-05	0.000166	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NRG1—thyroid cancer	1.2e-05	0.000166	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—HRAS—thyroid cancer	1.19e-05	0.000163	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	1.18e-05	0.000163	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NDUFA13—thyroid cancer	1.14e-05	0.000157	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HRAS—thyroid cancer	1.14e-05	0.000157	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.13e-05	0.000156	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NRG1—thyroid cancer	1.13e-05	0.000155	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SLC5A5—thyroid cancer	1.12e-05	0.000154	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SST—thyroid cancer	1.11e-05	0.000153	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NRG1—thyroid cancer	1.11e-05	0.000153	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.08e-05	0.000149	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CHST14—thyroid cancer	1.08e-05	0.000148	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—HRAS—thyroid cancer	1.07e-05	0.000148	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CALCA—thyroid cancer	1.07e-05	0.000148	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—AKT1—thyroid cancer	1.05e-05	0.000144	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—NRAS—thyroid cancer	1.05e-05	0.000144	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PTEN—thyroid cancer	1.04e-05	0.000143	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NRAS—thyroid cancer	1.03e-05	0.000141	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—RXRA—thyroid cancer	1.01e-05	0.00014	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TERT—thyroid cancer	1.01e-05	0.000139	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—AKT1—thyroid cancer	1.01e-05	0.000138	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TERT—thyroid cancer	9.99e-06	0.000137	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PTEN—thyroid cancer	9.95e-06	0.000137	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	9.87e-06	0.000136	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDK1—thyroid cancer	9.71e-06	0.000134	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HIF1A—thyroid cancer	9.67e-06	0.000133	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HIF1A—thyroid cancer	9.55e-06	0.000131	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PPARG—thyroid cancer	9.54e-06	0.000131	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—RXRA—thyroid cancer	9.4e-06	0.000129	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TPR—thyroid cancer	9.27e-06	0.000128	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NRAS—thyroid cancer	9.25e-06	0.000127	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—thyroid cancer	9.24e-06	0.000127	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	9.12e-06	0.000126	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	9.09e-06	0.000125	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—KRAS—thyroid cancer	9.01e-06	0.000124	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NRAS—thyroid cancer	8.88e-06	0.000122	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—KRAS—thyroid cancer	8.84e-06	0.000122	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HPGD—thyroid cancer	8.67e-06	0.000119	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	8.27e-06	0.000114	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TPR—thyroid cancer	8.08e-06	0.000111	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	8.08e-06	0.000111	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTEN—thyroid cancer	8.05e-06	0.000111	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KRAS—thyroid cancer	7.96e-06	0.000109	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PRKAR1A—thyroid cancer	7.95e-06	0.000109	CbGpPWpGaD
Dabrafenib—RAF1—Disease—BRAF—thyroid cancer	7.91e-06	0.000109	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—thyroid cancer	7.86e-06	0.000108	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NRG1—thyroid cancer	7.79e-06	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—HRAS—thyroid cancer	7.66e-06	0.000105	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KRAS—thyroid cancer	7.64e-06	0.000105	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—HRAS—thyroid cancer	7.51e-06	0.000103	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—thyroid cancer	7.5e-06	0.000103	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NRAS—thyroid cancer	7.19e-06	9.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TERT—thyroid cancer	7e-06	9.62e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC5A5—thyroid cancer	6.94e-06	9.55e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	6.82e-06	9.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—thyroid cancer	6.76e-06	9.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—thyroid cancer	6.76e-06	9.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HIF1A—thyroid cancer	6.69e-06	9.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—thyroid cancer	6.63e-06	9.13e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTEN—thyroid cancer	6.54e-06	9e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	6.5e-06	8.95e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—thyroid cancer	6.49e-06	8.94e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—thyroid cancer	6.41e-06	8.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—thyroid cancer	6.39e-06	8.79e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—thyroid cancer	6.18e-06	8.51e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC5A5—thyroid cancer	6.05e-06	8.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTEN—thyroid cancer	6.04e-06	8.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—thyroid cancer	5.97e-06	8.22e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—thyroid cancer	5.93e-06	8.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—NRAS—thyroid cancer	5.89e-06	8.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—thyroid cancer	5.84e-06	8.04e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—RXRA—thyroid cancer	5.83e-06	8.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—thyroid cancer	5.73e-06	7.89e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.67e-06	7.8e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTEN—thyroid cancer	5.64e-06	7.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTEN—thyroid cancer	5.57e-06	7.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BRAF—thyroid cancer	5.54e-06	7.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NRAS—thyroid cancer	5.38e-06	7.41e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—thyroid cancer	5.26e-06	7.23e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—RXRA—thyroid cancer	5.08e-06	6.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—thyroid cancer	5.07e-06	6.98e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—thyroid cancer	5.04e-06	6.94e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NRAS—thyroid cancer	5.03e-06	6.92e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TPR—thyroid cancer	4.98e-06	6.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NRAS—thyroid cancer	4.97e-06	6.84e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	4.9e-06	6.74e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—thyroid cancer	4.67e-06	6.42e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—thyroid cancer	4.64e-06	6.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—thyroid cancer	4.63e-06	6.38e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTEN—thyroid cancer	4.4e-06	6.05e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—thyroid cancer	4.33e-06	5.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—thyroid cancer	4.31e-06	5.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—thyroid cancer	4.28e-06	5.89e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTEN—thyroid cancer	4.07e-06	5.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—thyroid cancer	4.04e-06	5.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—thyroid cancer	3.94e-06	5.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTEN—thyroid cancer	3.9e-06	5.37e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—thyroid cancer	3.85e-06	5.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—thyroid cancer	3.81e-06	5.24e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—thyroid cancer	3.77e-06	5.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	3.73e-06	5.13e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—thyroid cancer	3.68e-06	5.07e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—thyroid cancer	3.68e-06	5.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—thyroid cancer	3.64e-06	5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NRAS—thyroid cancer	3.48e-06	4.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—thyroid cancer	3.48e-06	4.79e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—thyroid cancer	3.25e-06	4.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—thyroid cancer	3.21e-06	4.42e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—thyroid cancer	3.21e-06	4.41e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—RXRA—thyroid cancer	3.13e-06	4.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—thyroid cancer	3e-06	4.12e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—thyroid cancer	2.9e-06	3.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—thyroid cancer	2.66e-06	3.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—thyroid cancer	2.55e-06	3.5e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—thyroid cancer	2.53e-06	3.49e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTEN—thyroid cancer	2.53e-06	3.48e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—thyroid cancer	2.52e-06	3.47e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—thyroid cancer	2.35e-06	3.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—thyroid cancer	2.25e-06	3.09e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTEN—thyroid cancer	2.2e-06	3.03e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—thyroid cancer	1.98e-06	2.72e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.55e-06	2.14e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—thyroid cancer	1.46e-06	2e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTEN—thyroid cancer	1.36e-06	1.87e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—thyroid cancer	1.27e-06	1.74e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—thyroid cancer	7.81e-07	1.08e-05	CbGpPWpGaD
